Jefferies Initiates Coverage On Arcutis Biotherapeutics with Buy Rating, Announces Price Target of $15
Portfolio Pulse from Benzinga Newsdesk
Jefferies has initiated coverage on Arcutis Biotherapeutics with a Buy rating and set a price target of $15.
August 28, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies has initiated coverage on Arcutis Biotherapeutics with a Buy rating and a price target of $15, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target by a reputable firm like Jefferies is likely to positively influence investor sentiment and could lead to an increase in ARQT's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100